U.S. regulators have approved a pill version of the weight-loss drug Wegovy. This gives Novo Nordisk an edge over Eli Lilly, whose similar drug is still under review. Both pills mimic a hormone that controls appetite. The Wegovy pill is expected to be available within weeks.
KOB 4's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
U.S. regulators have approved a pill version of the weight-loss drug Wegovy. This gives Novo Nordisk an edge over Eli Lilly, whose similar drug is still under review. Both pills mimic a hormone that controls appetite. The Wegovy pill is expected to be available within weeks.
The FDA on Monday approved a daily pill version of Novo Nordisk’s blockbuster drug Wegovy, making it the first oral GLP-1 obesity treatment cleared for use without injections.
U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.
Wegovy's pill has become the first oral GLP-1 medication approved by the FDA, showing a 16.6% mean weight loss in trials. The pill is slated to launch January 2026.
